caffeine citrate - Profile

What are the generic drug sources for caffeine citrate and what is the scope of freedom to operate?

Caffeine citrate is the generic ingredient in two branded drugs marketed by Hikma, Am Regent, Eugia Pharma, Exela Pharma Science, Fresenius Kabi Usa, Micro Labs, Sagent Pharms, Sun Pharm, and Exela Pharma, and is included in fourteen NDAs. Additional information is available in the individual branded drug profile pages.

Summary for caffeine citrate

US Patents:	0
Tradenames:	2
Applicants:	9
NDAs:	14

US Patents and Regulatory Information for caffeine citrate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hikma	CAFCIT	caffeine citrate	SOLUTION;INTRAVENOUS	020793-001	Sep 21, 1999	AP	RX	Yes	Yes
Am Regent	CAFFEINE CITRATE	caffeine citrate	SOLUTION;INTRAVENOUS	077906-001	May 15, 2007	AP	RX	No	No
Eugia Pharma	CAFFEINE CITRATE	caffeine citrate	SOLUTION;INTRAVENOUS	205013-001	Sep 22, 2015		DISCN	No	No

EU/EMA Drug Approvals for caffeine citrate

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Gennisium Pharma	Gencebok	caffeine citrate	EMEA/H/C/005435Treatment of primary apnoea of premature newborns.	Authorised	no	no	no	2020-08-19

Last updated: July 19, 2026

Caffeine Citrate Investment Scenario and Fundamentals Analysis: Patent, Exclusivity, FDA Status, and Generic/Biosimilar Risk

Caffeine citrate is a niche, off-patent neonatal stimulant with limited commercial upside outside established hospital formularies. Core investment drivers are (1) FDA/market access continuity for existing formulations, (2) pricing and procurement dynamics in NICUs, (3) incremental demand from NICU utilization and neonatal care standards, and (4) supply-chain and manufacturing reliability more than IP-driven exclusivity. The risk profile is dominated by generic entry in most major markets, with patent estates that typically sit behind formulation and manufacturing improvements rather than broad composition coverage.

If you screen caffeine citrate as an investable asset, treat it as a procurement and supply-execution bet in a largely genericized landscape, not an IP moat bet.

---

What is caffeine citrate’s FDA status and who markets it?

Featured snippet answer: Caffeine citrate is approved for neonatal apnea. The market is dominated by branded and generic supply, with FDA product listings organized by strength and dosage form, typically injectable caffeine citrate for hospital use.

Mechanism and indication scope

• Indication: neonatal apnea (commonly “apnea of prematurity”).
• Clinical positioning: respiratory drive stimulant used in NICUs; dosing is weight-based and protocol-driven.

Dosage forms that matter commercially

• Injectable solution: the most relevant for acute NICU use and formulary adoption.
• Oral solutions are less frequently the procurement driver in NICUs, depending on local pathways.

Commercial implication

Because NICU adoption is protocol-based, switching costs are driven by hospital pharmacy workflows, drug stability/handling, and supply reliability. When multiple suppliers are available, procurement pressure is the main pricing determinant.

Data you should tie to diligence

• Unit volume by NICU discharge/gestational age cohorts
• Tender and contract pricing (GPO and IDN channels)
• Stock-out history and lot release cadence for injection SKUs
• Regulatory continuity: inspections, GMP status, and manufacturing site stability

---

What patents protect caffeine citrate, and how strong is the patent estate?

Featured snippet answer: Caffeine citrate’s core compound is long since off patent; protection typically concentrates in secondary inventions (formulation, manufacturing, packaging, and specific process improvements) rather than broad composition-of-matter exclusivity.

Patent estate reality for “legacy” small molecules

For older small-molecule APIs like caffeine (and salts), composition coverage usually expires years earlier. The practical IP question for investors is whether any active patents still control:

• specific liquid formulations (concentration, excipient systems)
• container-closure systems (stability and extractables)
• manufacturing process steps
• handling/premixing or dilution-ready presentations
• method-of-use claims that materially change dosing or monitoring

How to score strength for an investment model

Use an “enforceability and remaining term” lens:

• Remaining term through expected product life cycle (tender cycles, hospital contracts)
• Claim scope coverage of the exact dosage form and concentration used in NICUs
• Likelihood of invalidation (obviousness around known caffeine formulations)
• Procedural posture (any injunction risk or settlement signals)

Investment interpretation

Even if secondary patents exist, enforcement against generics often depends on whether the generic’s formulation and process map onto the claims. For procurement products, generic competition can still proceed while litigation runs if the Orange Book pathway and carve-outs allow it.

---

When does caffeine citrate lose exclusivity, and what is the generic entry timeline?

Featured snippet answer: For caffeine citrate, exclusivity is generally not the limiting factor for long-term generic access; practical entry is determined by Orange Book listing status, patent expiry, and any ongoing patent challenges.

Exclusivity framework investors model

• Patent-driven exclusivity: utility or formulation patents listed in the Orange Book
• Regulatory exclusivity: orphan, pediatric, or new chemical entity exclusivity (often not applicable to legacy drugs like caffeine citrate)
• Exclusivity-limited supply agreements: some hospitals use long-term contracts that delay switching even after legal freedom to operate exists

Timeline structure to use in diligence

Model market impact in phases:

1. Legal freedom to operate (FTO) achieved via expiry or settlement
2. ANDA launch scheduling and supply onboarding
3. Hospital formulary update and protocol adoption
4. Contract rebids and price compression

Investment implication

Most value is captured early in the genericization window and then erodes through price compression. New entrants that win share do so by supply reliability and contracting, not by maintaining a price premium.

---

What is the Orange Book status of caffeine citrate (ANDAs, listed patents, and exclusivity)?

Featured snippet answer: Caffeine citrate’s Orange Book listings typically show either expired composition patents or limited, product-specific formulation/process patents, if any remain.

What to extract from the Orange Book for an investment memo

For each relevant listed drug product (strength, dosage form):

• Approved application number(s)
• Listed patents with expiration dates
• Patent type codes (composition, formulation, method of use)
• Any exclusivity code(s)

How Orange Book status affects business risk

• If no unexpired patents remain that read on generic products, ANDA entry is mainly supply execution.
• If specific patents remain, the risk becomes:
  • Paragraph IV litigation burden
  • Potential injunction or “design-around” requirement
  • Contracting delays due to payer risk management

---

What Paragraph IV challenges exist for caffeine citrate, and how do they affect generic launch risk?

Featured snippet answer: Paragraph IV risk is typically lower for legacy products unless formulation/process patents remain unexpired and are plausibly infringed by the generic’s exact dosage presentation.

Investor-facing generic risk model

Score each active listing (if any) on:

• “Read-on” probability to generic claims
• Litigation timelines and likelihood of settlement
• Injunction feasibility based on district history and claim strength

Business implication

Even one strong, remaining formulation patent can delay launch in the same strength/dosage form. Without such patents, the market tends to move quickly to multiple-source procurement and price compression.

---

How many patents cover caffeine citrate formulations (injection, concentration, excipients), and which ones matter for infringement?

Featured snippet answer: Coverage usually clusters by the specific liquid injection formulation and manufacturing method, rather than across all caffeine citrate presentations.

Formulation claim hotspots

For liquid injections, the patents that matter most tend to involve:

• excipient ratios affecting stability and pH
• buffering systems
• tolerance of storage conditions (temperature excursions)
• container-closure compatibility
• manufacturing process conditions that control particle formation or degradation

Infringement mapping for diligence

Investors should model whether a generic’s label-conformant formulation is likely to:

• use the same buffer and excipient system within the claimed ranges
• meet identical physicochemical parameters defined in claims
• replicate process conditions that generate the claimed product quality attributes

---

Which companies supply caffeine citrate in the US and how competitive is the landscape?

Featured snippet answer: Competition is multi-source, anchored by generic suppliers and at least one established branded or legacy-manufacturing channel; the differentiator is supply reliability and contract pricing more than therapeutic innovation.

Competitive dimensions that drive margins

• Contracting power in IDNs and group purchasing organizations
• GMP throughput and lot-release reliability
• Hospital preference for predictable supply and consistent packaging
• Readiness for sudden demand spikes (seasonal NICU load shifts, public health events, or guideline changes)

Investment implication

Margins compress quickly once multiple ANDA products are on contract. The investable edge typically shifts to:

• supply-chain robustness
• production scalability
• regulatory continuity and inspection resilience

---

What generic entry risks exist for caffeine citrate, and how should an investor model them?

Featured snippet answer: Entry risk is primarily price and channel loss risk after additional ANDA availability, plus operational risk (GMP, supply continuity) rather than blockbuster litigation.

Model the two big risk vectors

1. Legal/Regulatory entry timing risk
   • Orange Book listing status and any active litigation
   • Launch delays due to final labeling readiness or inspections
2. Commercial execution risk
   • Hospital contracting timing
   • Supply reliability and backorder exposure
   • Ability to match unit economics in tender pricing

Practical investment conclusion

A credible base case assumes margin compression after each additional generic entrant and focuses upside on share capture through stable supply and procurement contracting.

---

What patent litigation affects caffeine citrate, and what are common settlement patterns?

Featured snippet answer: For legacy injectable small molecules, litigation patterns often end in settlements that allow generic entry under agreed timelines, sometimes with design-around formulations or launch sequencing.

What settlement signals matter to investors

• whether settlement allows “at-risk” early entry or moves to a later launch date
• whether the settlement binds only the first filer or broadly
• whether design-around is needed for a specific concentration or presentation

Why litigation is not the primary driver

Most caffeine citrate demand is steady and protocol-driven. Litigation affects launch dates, but once multiple sources exist, procurement price is the dominant margin determinant.

---

What regulatory milestones and manufacturing constraints matter for caffeine citrate injections?

Featured snippet answer: For sterile injectables, the critical constraints are GMP compliance, aseptic processing capability, batch release timelines, and stability across the labeled shelf-life.

Regulatory diligence checklist investors use

• inspection history for the manufacturing site(s)
• sterile manufacturing and fill-finish capacity
• batch rejection rates and OOS frequency
• analytical method validation stability programs
• lot distribution and cold-chain requirements (if applicable)

Manufacturing risk translation

A supply disruption can trigger immediate contract repricing and accelerated re-tendering, even when the drug is legally genericized.

---

How does caffeine citrate compare with other neonatal apnea treatments for investment relevance?

Featured snippet answer: Caffeine citrate’s investment profile is shaped by generic pressure and procurement dynamics; compared with newer respiratory stimulants, it is less exposed to R&D-driven innovation risk but more exposed to tender-driven price compression.

Comparison dimensions

• Competitive substitution: whether formularies can switch between brands/generics without clinical friction
• Protocol entrenchment: whether guidelines lock dosing and product characteristics
• Supply reliability: which product wins when multiple are legally available

Investment implication

Caffeine citrate behaves like a low-growth, high-reliability procurement commodity. The better investments are those with durable manufacturing throughput and contracting access.

---

Revenue exposure: where does value sit for caffeine citrate suppliers?

Featured snippet answer: Value is concentrated in hospital procurement channels, tender contracts, and stable supply allocations rather than in brand premium.

Revenue model components

• NICU unit demand (premature population and treatment duration)
• contract pricing per vial and per mg equivalent
• payer mix: hospitals and integrated delivery networks
• fulfillment reliability and customer retention

Margin drivers

• scale economies in aseptic manufacturing
• yield and rejection rates
• logistics and packaging costs (sterile packaging compliance)
• tender bid strategy and customer concentration risk

---

Which business model is most investable: branded legacy, generic manufacturer, or contract manufacturer?

Featured snippet answer: In caffeine citrate, the investable angle is usually the generic or contract manufacturing model that can secure predictable channel demand and sustain GMP-grade supply, not the branded model.

Model-by-model

• Branded/legacy manufacturer: faces margin pressure as generics expand; investment returns track supply share and contracting discipline.
• Generic manufacturer: best-positioned where it has stable manufacturing sites, fast ANDA launches, and strong distribution.
• Contract manufacturer: can capture recurring volume but needs customer diversification because sterile injectables face regulatory discontinuity risk.

---

Key Takeaways

• Caffeine citrate is primarily a NICU procurement product with investment value driven by supply execution and contract pricing.
• The core compound is long off broad composition exclusivity; remaining IP is typically formulation or manufacturing-specific.
• Generic entry risk is more about price compression and channel loss timing than about blocking litigation.
• Regulatory and manufacturing continuity are the dominant operational variables for earnings stability.
• Investor diligence should weight Orange Book status only to the extent it affects unexpired formulation/process patents and any active Paragraph IV litigation impacting launch timing.

---

FAQs

1) Is caffeine citrate considered a controlled substance for manufacturing or distribution?
2) Do NICU protocols require a specific caffeine citrate concentration or presentation that affects generic switching?
3) What aseptic manufacturing steps typically drive batch rejection risk for injectable caffeine citrate?
4) Are there known stability or pH-related formulation issues that constrain alternative generics?
5) How do tender cycles in US hospital networks typically impact pricing for generic injectable medicines like caffeine citrate?

---

References

1. FDA. “Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.” U.S. Food and Drug Administration.
2. FDA. “Approved Drug Products.” U.S. Food and Drug Administration.
3. FDA. “ANDA Submissions.” U.S. Food and Drug Administration.